Department of Medicine, Marquette University, 1120 W, Wisconsin Avenue, Wilwaukee, WI 53233, USA.
J Cardiovasc Magn Reson. 2011 Aug 3;13(1):37. doi: 10.1186/1532-429X-13-37.
Cardiovascular magnetic resonance (CMR) allows volumetric carotid plaque measurement that has advantage over 2-dimensional ultrasound (US) intima-media thickness (IMT) in evaluating treatment response. We tested the hypothesis that 6-month statin treatment in patients with carotid plaque will lead to plaque regression when measured by 3 Tesla CMR but not by IMT.
Twenty-six subjects (67 ± 2 years, 7 females) with known carotid plaque (> 1.1 mm) and coronary or cerebrovascular atherosclerotic disease underwent 3T CMR (T1, T2, proton density and time of flight sequences) and US at baseline and following 6 months of statin therapy (6 had initiation, 7 had increase and 13 had maintenance of statin dosing). CMR plaque volume (PV) was measured in the region 12 mm below and up to 12 mm above carotid flow divider using software. Mean posterior IMT in the same region was measured. Baseline and 6-month CMR PV and US IMT were compared. Change in lipid rich/necrotic core (LR/NC) and calcification plaque components from CMR were related to change in PV.
Low-density lipoprotein cholesterol decreased (86 ± 6 to 74 ± 4 mg/dL, p = 0.046). CMR PV decreased 5.8 ± 2% (1036 ± 59 to 976 ± 65 mm3, p = 0.018). Mean IMT was unchanged (1.12 ± 0.06 vs. 1.14 ± 0.06 mm, p = NS). Patients with initiation or increase of statins had -8.8 ± 2.8% PV change (p = 0.001) while patients with maintenance of statin dosing had -2.7 ± 3% change in PV (p = NS). There was circumferential heterogeneity in CMR plaque thickness with greatest thickness in the posterior carotid artery, in the region opposite the flow divider. Similarly there was circumferential regional difference in change of plaque thickness with significant plaque regression in the anterior carotid region in region of the flow divider. Change in LR/NC (R = 0.62, p = 0.006) and calcification (R = 0.45, p = 0.03) correlated with PV change.
Six month statin therapy in patients with carotid plaque led to reduced plaque volume by 3T CMR, but ultrasound posterior IMT did not show any change. The heterogeneous spatial distribution of plaque and regional differences in magnitude of plaque regression may explain the difference in findings and support volumetric measurement of plaque. 3T CMR has potential advantage over ultrasound IMT to assess treatment response in individuals and may allow reduced sample size, duration and cost of clinical trials of plaque regression.
心血管磁共振(CMR)允许对颈动脉斑块进行容积测量,与评估治疗反应的二维超声(US)内膜中层厚度(IMT)相比具有优势。我们检验了以下假设,即 6 个月的他汀类药物治疗可导致颈动脉斑块患者的斑块消退,这可通过 3T CMR 进行测量,但不能通过 IMT 进行测量。
26 名受试者(67 ± 2 岁,7 名女性)患有颈动脉斑块(> 1.1 毫米)和冠状动脉或脑血管动脉粥样硬化性疾病,在基线时和接受他汀类药物治疗 6 个月后接受 3T CMR(T1、T2、质子密度和飞行时间序列)和 US 检查(6 名患者开始使用他汀类药物治疗,7 名患者增加剂量,13 名患者维持他汀类药物剂量)。使用软件在颈动脉分流器下方 12 毫米至上方 12 毫米的区域内测量 CMR 斑块体积(PV)。在同一区域测量平均后壁 IMT。比较基线和 6 个月时的 CMR PV 和 US IMT。比较 CMR 中富含脂质/坏死核心(LR/NC)和钙化斑块成分的变化与 PV 的变化。
低密度脂蛋白胆固醇降低(86 ± 6 至 74 ± 4mg/dL,p = 0.046)。CMR PV 降低 5.8 ± 2%(1036 ± 59 至 976 ± 65mm3,p = 0.018)。平均 IMT 无变化(1.12 ± 0.06 至 1.14 ± 0.06mm,p = NS)。开始或增加他汀类药物治疗的患者的 PV 变化为-8.8 ± 2.8%(p = 0.001),而维持他汀类药物剂量的患者的 PV 变化为-2.7 ± 3%(p = NS)。CMR 斑块厚度存在周向异质性,颈动脉后壁最厚,在分流器对面的位置。同样,斑块厚度的变化存在周向区域性差异,在分流器区域的颈动脉前区域存在显著的斑块消退。LR/NC(R = 0.62,p = 0.006)和钙化(R = 0.45,p = 0.03)的变化与 PV 变化相关。
颈动脉斑块患者接受 6 个月的他汀类药物治疗后,通过 3T CMR 可减少斑块体积,但超声后壁 IMT 无明显变化。斑块的空间分布不均匀,斑块消退的幅度存在区域性差异,这可能解释了两种发现的差异,并支持对斑块进行容积测量。3T CMR 与超声 IMT 相比具有评估个体治疗反应的潜在优势,可能会减少临床试验中斑块消退的样本量、持续时间和成本。